Allogeneic ‘off‐the‐shelf’ <scp>SARS</scp>‐<scp>C</scp>o<scp>V</scp>‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease
Allogeneic SARS-CoV-2-specific T-cell therapy provides a platform to rapidly administer T cells to high-risk COVID-19 patients. It was associated with a reduced viral load and increased SARS-CoV-2-specific T-cell responses in the majority of treated patients.
Authors
- Leone Beagley
- Pauline Crooks
- Corey Smith (ORCID: https://orcid.org/0000-0002-7550-9595)
- Srividhya Swaminathan (ORCID: https://orcid.org/0000-0002-0750-3650)
- Arushi Mahajan (ORCID: https://orcid.org/0009-0007-6948-0689)
- Matthew D. Solomon (ORCID: https://orcid.org/0000-0001-7846-9296)
- Siok‐Keen Tey (ORCID: https://orcid.org/0000-0001-9567-382X)
- Andrea S. Henden (ORCID: https://orcid.org/0000-0003-2261-169X)
- Katie E. Lineburg (ORCID: https://orcid.org/0000-0002-5712-2610)
- Glen Kennedy (ORCID: https://orcid.org/0000-0002-7171-0435)
- Ricky Nelles (ORCID: https://orcid.org/0000-0002-0246-5691)
- Rajiv Khanna (ORCID: https://orcid.org/0000-0003-2241-0353)
- Archana Panikkar
- Michelle A. Neller (ORCID: https://orcid.org/0000-0002-2457-1508)
- Shannon E. Best
- E. H. M. Wright
- Hilary Reddiex
- Laëtitia Le Texier
- Jyothy Raju
Institutions
- The University of Queensland (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Royal Brisbane and Women's Hospital (AU)
Publication Details
- Journal
- Clinical & Translational Immunology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/cti2.70038
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Queensland Health
- QIMR Berghofer Medical Research Institute
- Australian Government
- University of Queensland